Back to Search
MAURA DICKLER, MD
MD
Medical Oncology Physician
NPI: 1730150764Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
198593(NY)
Research & Publications (20)
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
PMID 18496750·Breast Cancer Res Treat·2009
3-trial
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
PMID 19047117·Clin Cancer Res·2008
3-trial
Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
PMID 16205767·Nat Clin Pract Oncol·2005
4-observational
The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
PMID 11795345·Ann N Y Acad Sci·2001
4-observational
Hepatitis C virus infection does not preclude standard breast cancer-directed therapy.
PMID 19299241·Clin Breast Cancer·2009
8-other
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
PMID 18323546·J Clin Oncol·2008
3-trial
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
PMID 17952589·Breast Cancer Res Treat·2008
2-rct
Aromatase inhibitors and arthralgia: a growing pain?
PMID 19322950·Oncology (Williston Park)·2008
8-other
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.
PMID 18952555·Clin Breast Cancer·2008
3-trial
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
PMID 18824714·J Clin Oncol·2008
3-trial
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
PMID 17504999·Clin Cancer Res·2007
3-trial
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
PMID 18160686·N Engl J Med·2007
3-trial
When you look matters: the effect of assessment schedule on progression-free survival.
PMID 17374832·J Natl Cancer Inst·2007
8-other
Small-Fiber Neuropathy Associated with Capecitabine (Xeloda)-induced Hand-foot Syndrome: A Case Report.
PMID 19078798·J Clin Neuromuscul Dis·2006
8-other
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
PMID 15681523·J Clin Oncol·2005
3-trial
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
PMID 15803362·Breast Cancer Res Treat·2005
3-trial
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
PMID 15355903·Clin Cancer Res·2004
3-trial
Aromatase inhibitors for hormonal therapy of early-stage breast cancer.
PMID 15242248·Curr Opin Investig Drugs·2004
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 205 E 64TH ST
NEW YORK, NY 10021 - Phone
- (212) 639-2000
Quick Facts
- NPI
- 1730150764
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile